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Abstract
Background: Due to its anti-apoptotic and anti-proliferative contradictory functions, BCL2 role in breast carcinoma progression is not clearly understood. 
The purpose of this study was to highlight BCL2 expression during metastatic progression of invasive breast carcinoma of no special type (NST).
Materials and methods: The specimens, primary tumors and corresponding lymph node metastases (LNM) from 84 patients were immunostained for 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER)-2, basal cytokeratin CK5, nuclear protein Ki67 and 
B-cell lymphoma (Bcl)-2 receptor. 
Results: BCL2 expression was higher at primary site than in axillary metastases. Its score correlates positively with hormone receptors’ level and negatively 
with HER2, CK5 and Ki67 at both sites. Switch of molecular profile was determined in 22.62% of cases. BCL2 expression was not influenced by subtypes 
switch. Changes of BCL2 expression were found in 25% of cases with stable molecular subtype. The Luminal A and Luminal B/Ki67 were encountered 
in the majority of BCL2 transitions, mainly from positive to negative state. 
Conclusions: Molecular subtypes and BCL2 expression are not stable during tumor progression and metastatic development. In the present study we 
established immunohistochemically that BCL2 is not influenced by subtypes’ transitions. BCL2 switches were encountered only in cases with a stable 
HER2, Luminal A or B phenotypes. We expect a further confirmation of our results by other research groups.
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Introduction
Breast carcinoma is the most common cause of death 
among women, and despite all efforts the drivers of this 
malignancy are not completely elucidated. Cancer occurs as 
the result of a disturbance in the balance between cell growth 
and cell death. Over-expression of anti-apoptotic genes or 
under-expression of pro-apoptotic genes can result in the 
lack of cell death, mechanisms that have been demonstrated 
in breast cancer too. Besides well-known prognostic factors, 
such as tumor size, histological type and grade, vascular in-
vasion, identifying of new molecular factors has become the 
objective of many research studies. One of these potential 
markers is B-cell lymphoma (Bcl)-2 receptor.
BCL2 is a member of regulator proteins that regulate cell 
death, by either acting as pro-apoptotic or anti-apoptotic 
[1, 2]. BCL2 is specifically considered as an important anti-
apoptotic protein and is thus classified as an oncogene. This 
protein, apart from its well-known inhibition of apoptosis, 
can also inhibit progression of the cell cycle by delaying entry 
into the S phase and maintaining cells in the G0 phase.
BCL2 in addition to HER2 and p53 is considered a tumor-
related protein that has the potential to further improve indi-
vidualization of patient management, by predicting response 
to chemotherapy, hormone therapy and radiotherapy [3]. Due 
to its anti-apoptotic function BCL2 is considered an impor-
tant factor in the modulation of hormonal/anti-hormonal 
responsiveness exhibited by tumors [4]. Patients with elevated 
BCL2 immunostaining appeared to have the greatest benefit 
from endocrine therapy. In addition, BCL2 overexpression is 
associated with favorable outcome and its effect in relation-
ship to estrogen receptor (ER) status. Some data suggest that 
BCL2 expression is a predictive factor for response to che-
motherapy particularly in anthracycline-based chemotherapy 
[5]. Other report showed this marker has no significant value 
for the therapeutic strategy [6]. Contrary, clinicopathological 
data suggests that BCL2 expression correlates with aggressive, 
prometastatic behavior in breast cancer [7]. 
In the last decade, the gene analysis led to identification 
of molecular subtypes and defined the gene-expression 
prognostic signatures [8, 9]. By analysis of protein expres-
sion using immunohistochemistry it has been identified that 
molecular subtypes characterized with surrogate markers 
are similar to those derived from gene expression arrays 
[10, 11]. Nowadays, it seems to be important to investigate 
the molecular profile of metastases too. Recent data reveal 
the instability of receptors throughout the metastatic process 
[12, 13]. This supports the hypothesis that the malignant 
phenotype is not pre-determined, but continues to evolve 
throughout its natural history. In comparison to basic, five 
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commonly accepted markers in breast cancer stratification 
(ER, PR, HER2, CK5, Ki67), nowadays is not clear the future 
of BCL2 positive tumor cells in the lymphonodal environ-
ment. The aim of the current study was to compare BCL2 
expression from primary tumor with corresponding lymph 
node metastases (LNM) in association with hormone re-
ceptors (estrogen (ER), progesterone (PR)), HER2 (human 
epidermal growth factor receptor-2), basal cytokeratin CK5 
status and molecular subtypes.
Material and methods
Patients. In this retrospective study there were analyzed 
specimens (breast carcinoma of no special type and corre-
sponding axillary lymph node metastases) from 84 patients 
of 33-86 years old. In all cases patients underwent radical 
mastectomy and lymph nodes dissection, without prior 
chemo- and radiotherapy. Histopathological diagnosis was 
assessed by two pathologists and cases suitable for immuno-
histochemistry were carefully selected.
Ethical issues. This study was based on patients’ informed 
consent and approved by the Ethics Committee of the Nicolae 
Testemitsanu State University of Medicine and Pharmacy 
from Chisinau, the Republic of Moldova (approval number 
21/13/31.03.2014).
Specimen processing and immunohistochemistry. 
The specimens were fixed in 10% phosphate buffered for-
malin for 24-48h and paraffin embedded (Paraplast High 
Melt, Leica Biosystems).  Primary tumor and its LNM were 
placed in one block and 5-μm thick step sections were cut. 
The immunohistochemical assessment included 6 surrogate 
markers (from Leica Biosystems, except HER2), for ER (clone 
ER/6F11), PR (clone Pr16), human epidermal growth factor 
receptor 2 (HER2/polyclonal/ DakoCytomation), marker of 
proliferation Ki67 (clone K2), basal cytokeratin CK5 (clone 
XM26) and BCL2 (clone BCL2/100/D5). Incubation with 
primary antibodies was followed by the use of HercepTest 
PharmDx Kit (DakoCytomation) and Bond Polymer Refine 
Detection System (Leica Biosystems, Newcastle Upon Tyne, 
UK). All cases were evaluated also by FISH as international 
rules recommend (PathVysion HER-2 DNA Probe Kit II, 
Abbot). Slides were processed automatically on Leica Bond-
Max autostainer (Leica Microsystems GmbH, Wetzlar, Ger-
Fig. 1.  Representative images of ER, PR, HER2, CK5, Ki67, BCL2 immunohistochemical staining in primary breast 
carcinoma and corresponding lymphonodal metastases (color version look on the front page of the cover).
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many). The hematoxylin solution, Harris modified (HHS32, 
SigmaAldrich) was used for counterstaining (fig.1).
Microscopic evaluation. The hormone receptors were 
scored as the percentage of nuclear positively stained cells 
from at least 1000 cells assessed. We followed the guidelines 
of ER and PR assessment purposed by Allred et al. [14]. Cases 
scored +1 – +3 were considered positive. The threshold of 
positivity was 10%. 
The HER2 assessments were done on LeicaBond Oracle 
HER2 IHC System (LeicaBiosystem). The HER2 status was 
interpreted in accordance with American Society of Clinical 
Oncology recommendations [15]. Cases interpreted as +2 
and +3 were considered positive. Leica HER2 control slides 
ensured the control and accuracy of our decisions.
We used a 14% threshold for Ki67. This marker, as well as 
hormone receptors were counted using a semi-quantitative 
method performed by Suciu et al. [16].
The basal cytokeratin CK5 was interpreted in Azoulay’s 
et al. manner [17]. Cases evaluated as +1 – +3 were consid-
ered positive. 
The BCL2 evaluation was based on Callagy et al. recom-
mendations: 0 – no staining; +1 – until 10% of cells show 
cytoplasmic pattern; +2 – 10-50%; +3 – more than 50% [18]. 
Cases scored as +2 and +3 were considered positive.
Based on Goldhirsch et al. recommendation we clustered 
molecular subtypes, as follows: ER+ and/or PR+, HER2−, CK5-,
Ki67<14% as Luminal A; ER+ and/or PR+, HER2+, CK5− as 
Luminal B/HER2;   ER+ and/or PR+, HER2−, CK5−, Ki67>14% 
as Luminal B/Ki67; ER+ and/or PR+, HER2+, CK5−, Ki67>14% 
as Luminal B/HER2/Ki67; ER−, PR−, HER2+, CK5− as HER2-
overexpressed; ER−, PR−, HER2− and  CK5+ as Basal-like; ER−, 
PR−, HER2− and  CK5- as unclassified [19].
Image acquisition and statistical analysis. A Nikon 
Eclipse 80i microscope with Nikon DS-Fi1 installed camera 
and Nis-elements BR 2.30 imaging software were used for 
microscopic evaluation (Nikon Instruments Europe BV). 
For descriptive statistics and Pearson’s correlation assess-
ment WinStat 2012.1 software was used (R. Fitch Software, 
Bad Krozingen, Germany). For all the tests a value of p£0.05 
was considered significant. In order to determine the shift-
ing direction of subtypes (from basal to Luminal and vice 
versa) unclassified subtype was assigned as “1”, Basal-like as 
“2”, HER2+ as “3, Luminal B/HER2-“4”, Luminal B/HER2/
Ki67 –“5”, Luminal B/Ki67 –“6” and Luminal A was equated 
with “7”.
Results
Histological assessment revealed that the most frequent 
histological grade is G2, determined in 45 cases (53.6%), the 
share of G1 constitutes 6%/5 cases and G3 respectively in 
40.5%/34 cases. In relation to BCL2, the majority of positive 
scores were determined in cases with G2 (36 cases/42.9%) 
and G3 grades (23 cases/27.4%) In primary tumor the sur-
rogate markers for hormone receptors had the highest rate. 
BCL2 marker was positive in 62 cases/73.8% (tab. 1).
Table 1
Surrogate markers positivity in primary tu
Score
ER PR HER2 CK5 BCL2
No % No % No % No % No %
0 16 19.0 26 31.0 62 73.8 73 86.9 17 20.2
1 3 3.6 5 6.0 4 4.8 5 6.0 5 6.0
2 9 10.7 13 15.5 5 6.0 4 4.8 9 10.7
3 56 66.7 40 47.6 13 15.5 2 2.4 53 63.1
84 cases/100%
In relation to hormonal receptors the positive BCL2 
highest score was determined in cases with high expression 
of ER and PR receptors (tab. 2). And vice versa increasing of 
the HER2 and CK5 scores leads to decreasing of BCL2 score.
The proliferation marker Ki67 was considered positive 
(≥14) in 50 cases/59.52% of primary tumors. A positive BCL2 
was accompanied with positive Ki67 (≥14) in 32 cases/38.10% 
and in 30 cases/35.71% with a Ki67<14. In 18 cases/21.43% 
with high Ki67 level, BCL2 was considered negative.
The most frequent subtype at primary site was Luminal 
B (45 cases/53.6%), followed by Luminal A (26 cases/31%) 
and hormone-negative group (13 cases/15.5%). By compar-
ing the molecular profile and BCL2 score the highest rate of 
positivity was determined in Luminal B (39.29%) and Lumi-
nal A subtype (28.57%). The ratio of positive/negative BCL2 
marker in HER2 overexpressing subtype was 50/50 – (4.76% 
positive)/(4.76% negative). Appropriate ratio was determined 
for Luminal B/HER2/Ki67 – 4.76% positive/3.57% negative.
By comparing molecular profile of primary tumor and its 
LNM we determined a transition of subtype to another one 
in 19 cases/22.62%. We have to mention that BCL2 expres-
sion was stable in spite of these switches. Transitions of BCL2 
score (21 cases/25%) we found in the group, where molecular 
subtype at both sites is similar (tab. 3).
The highest percentage of BCL2 transition was encoun-
tered in Luminal A (8 cases/9.52%) and Luminal B/Ki67 
(8 cases/9.52%). HER2-positive cases (4 cases/4.76%) as-
sociated in primary tumor with positive BCL2, preserved 
molecular subtype in metastases, but became BCL2 negative. 
In the same manner, from positive BCL2 to negative, proceed 
Luminal B/Ki67 and Luminal A, in 7 cases/8.33% each. The 
main intention of BCL2 expression throughout metastatic 
process was rather loss than acquiring – in 19 cases (from 
21 changed), direction was from positive in primary tumor 
to negative in lymph node metastases. This is visible and by 
comparing the number of BCL2 positive cases at both sites 
– 62 cases/73.81% in primary tumor and 44 cases/52.38% 
in LNM.
BCL2 expression was analyzed in relation to proliferation 
activity. Tumors were grouped in 2 categories in accordance 
with Ki67 level: low proliferating (<14) and high proliferating 
(≥14). In 7 cases of Luminal A, where BCL2 changed during 
progression from negative to positive, the Ki67 had a low level 
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(<14). Other 7 cases of Luminal B/Ki67, where BCL2 from 
positive changed to negative, Ki67 preserved a high rate at 
both sites. If in Luminal subtypes the proliferation marker 
preserves similar quotes at both sites, in HER2-overexpressed 
it changed randomly. In the last 7 cases some correlation of 
Ki67 level with BCL2 switch was not observed. 
The statistical assays revealed significant, positive cor-
relation of BCL2 level with type of molecular profile, level 
of ER, PR markers and negative correlation with HER2, CK5 
and Ki67. 
Discussion
Breast carcinoma is the most common cause of death 
among women. Despite implementation of screening pro-
grams the incidence of this tumor worldwide is still increas-
ing. Besides well-known prognostic factors, such as tumor 
size, histological type and grade, vascular invasion, identify-
ing of new molecular factors became the objective of many 
research studies. Failure to undergo apoptosis is considered 
a major mechanism of cancerogenesis and chemoresistance.
A marker which is involved in inhibition of apoptosis 
is B-cell lymphoma (Bcl)-2 receptor. It has been shown to 
contribute to oncogenesis because it can transform and 
immortalize cells in cooperation with c-myc, ras or viral 
genes. Del Bufalo et al. consider that BCL2 overexpression 
enhances both tumorigenicity and metastatic potential of 
tumor cells by inducing metastasis-associated properties 
[20]. Rochaix et al. found that BCL2 expression in tumors 
Table 2
BCL2 expression in relation to ER, PR, HER2, CK5 surrogate markers score at primary tumor site
BCL2 score
No % No % No % No %
Total
ER score
0 1 2 3 No %
0 10 11.9 3 3.6 4 4.8 17 20.2
1 1 1.2 4 4.8 5 6
2 2 2.4 1 1.2 1 1.2 5 6.0 9 10.7
3 4 4.8 2 2.4 4 4.8 43 51.2 53 63.1
Total 16 19.05 3 3.57 9 10.71 56 66.67 84 100
PR score
BCL2 score
No % No % No % No %
No %
0 1  2 3 
0 10 11.9 3 3.6 2 2.4 2 2.4 17 20.2
1     2 2.4 3 3.6 5 6
2 3 3.6   2 2.4 4 4.8 9 10.7
3 13 15.5 2 2.4 7 8.3 31 36.9 53 63.1
Total 26 31.0 5 6.0 13 15.5 40 47.6 84 100
HER2 score
BCL2 score
No % No % No % No %
No %
0 1  2 3 
0 9 10.7 1 1.2 7 8.3 17 20.2
1 4 4.8 1 1.2   5 6
2 7 8.3   2 2.4 9 10.7
3 42 50.0 3 3.6 4 4.8 4 4.8 53 63.1
Total 62 73.8 4 4.8 5 6.0 13 15.5 84 100
CK5 score
BCL2 score
No % No % No % No %
No %
0 1  2 3 
0 10 11.9 4 4.8 1 1.2 2 2.4 17 20.24
1 5 6.0     5 6
2 8 9.5 1 1.2   9 10.7
3 50 59.5   3 3.6 53 63.1
Total 73 86.9 5 6.0 4 4.8 2 2.4 84 100
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was associated with a better differentiation of the cancers and 
particularly G1 – 100% of BCL2-positive tumors, G2 – 81%, 
G3 – 60% [21]. This assumption is in line with our results 
where majority (70.2%) of BCL2 positive cases was evaluated 
with G2 and G3 grades. Contradictory, Binder et al. presented 
a significant inverse correlation between histological grading 
and immunoreactivity for BCL2, confirmed by Ermiah et al. 
too [22,  23]. In our assays a statistically significant correla-
tion between histological grade and BCL2 was not found. 
Ermiah et al. consider that patients with positive expres-
sion of BCL2 had lower recurrence rate than BCL2-negative 
patients and better survival after median follow-up of 
47 months [23]. Recently, Yang et al. found significant relation 
between BCL2 negativity and good prognosis [5]. All related 
uniformities could have several explanations: unknown, other 
than anti-apoptotic function of BCL2, lack of homogeneity 
in studied group, differences in immunohistochemical assays 
and the cut-off used to define BCL2 positivity [24]. Lee et 
al. considered BCL2 positive case as “>0%” of stained cells 
and Dumontet et al. used a threshold of “>70%” positive 
cells [25, 26].
BCL2 is considered as modulator of hormonal/anti-
Table 3
Molecular subtypes and BCL2 evolution in tumor progression:  
a comparative study of primary tumor and corresponding metastases
Molecular subtype BCL2 expression No.
cases
%
Tm Mt Tm Mt
Unclassified Unclassified - - 2 2.38
77.4
Unclassified Unclassified + + 1 1.19
Basal-like Basal-like - - 1 1.19
HER2 HER2 - - 3 3.57
HER2 HER2 + - 4 4.76
Luminal A Luminal A - - 1 1.19
Luminal A Luminal A - + 1 1.19
Luminal A Luminal A + - 7 8.33
Luminal A Luminal A + + 13 15.48
Luminal B/HER2 Luminal B/HER2 - - 1 1.19
Luminal B/HER2 Luminal B/HER2 + - 1 1.19
Luminal B/HER2/Ki67 Luminal B/HER2 - - 1 1.19
Luminal B/HER2/Ki67 Luminal B/HER2/Ki67 - - 2 2.38
Luminal B/HER2/Ki67 Luminal B/HER2/Ki67 + + 1 1.19
Luminal B/HER2/Ki67 Luminal B/Ki67 + + 1 1.19
Luminal B/Ki67 Luminal B/Ki67 - - 1 1.19
Luminal B/Ki67 Luminal B/Ki67 - + 1 1.19
Luminal B/Ki67 Luminal B/Ki67 + - 7 8.33
Luminal B/Ki67 Luminal B/Ki67 + + 16 19.05
Basal-like Unclassified - - 1 1.19
22.6
HER2 Luminal B/HER2/Ki67 - - 1 1.19
Luminal A Unclassified + + 1 1.19
Luminal A Luminal B/HER2 + + 1 1.19
Luminal A Luminal B/Ki67 + + 2 2.38
Luminal B/HER2 Luminal A + + 1 1.19
Luminal B/HER2/Ki67 HER2 - - 1 1.19
Luminal B/HER2/Ki67 Luminal A + + 1 1.19
Luminal B/Ki67 Basal-like - - 1 1.19
Luminal B/Ki67 Luminal A - - 5 5.95
Luminal B/Ki67 Luminal A + + 4 4.76
Note: Molecular subtypes shifted cases are selected with Bold. BCl2 transitions (No and %) are primed with gray color. Tm – primary tumor, 
Mt – metastases.
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hormonal responsiveness exhibited by tumors. Binder et al. 
supposed that loss of BCL2 expression seems to induce the 
loss of hormonal regulation, increased dedifferentiation and 
deregulated proliferation [22]. Gee et al. determined that im-
munostaining for hormone receptors was strongly associated 
with that for the BCL2 protein, results which were confirmed 
by other researches later too [4, 27]. Authors supposed that 
this protein, like progesterone receptor, is under estrogen reg-
ulation via estrogen receptor. These results were confirmed 
also by a highly significant relationship between response to 
endocrine therapy and the presence of BCL2 protein. Indeed, 
BCL2 was more accurate predictor of response than estrogen 
receptor status. Patients who had a combination of BCL2 
high score and elevated ER level received the greatest benefit 
from endocrine therapy.  Our results concerning BCL2 and 
hormone receptors relationship are similar to Gee et al. [4]. 
In the literature the BCL2 was inversely related to c-erbB-2 
oncoprotein (as well to epidermal growth factor receptor or 
EGFR) [4, 22]. Petry et al. support the concept that ERBB2 
influences the expression of BCL2 family members to induce 
an anti-apoptotic phenotype [28]. Authors indicate that 
ERBB2 alters the expression of BCL2 in a way that leads to 
adverse prognosis. In our assays BCL2 correlated negatively 
with HER2 expression.
The anti-apoptotic function of BCL2 should predispose 
tumor to high proliferation. No associations were observed 
with Ki-67 proliferative status by some researches [4]. More, 
high proliferative activity assessed by Ki-67 correlated in-
versely with  BCL2  expression in primary tumor in Binde 
et al. and Zaha et al. experiments [22, 29]. Our results are 
complementary to above mentioned. 
CK5/6-positive breast carcinomas have a low BCL2 
expression and high proliferation rate [30]. Same data arise 
from our study too.
Korsching et al. consider that different cellular subgroups 
in the female breast give rise to subgroups of breast carcino-
mas with different protein expression and cytogenetic altera-
tion patterns that may be related to clinical behavior [30]. 
Approximately 80% of patients present hormone positive 
tumors. Dawson et al. established that prognostic value of 
BCL2 was present across molecular subtypes (ER+/Luminal, 
HER2+, HER2− and triple negative), and was independent 
of tumor size, grade and stage [31]. Cases with ER+/BCL2− 
pattern had a worse prognosis than those with ER−/BCL2+. 
There are several evidences which affirm the instability of 
molecular subtypes during metastatic process [12, 13, 32]. In 
our study BCL2 expression was stable throughout this transi-
tion and unexpectedly changed in the group where molecular 
subtype was the same at both sites. Our results are in line 
with Subhawong et al., which reported a downregulation of 
BCL2 expression in metastases in Luminal A subtype [33]. 
But in this report, patients (17 cases) underwent many cycles 
of adjuvant therapy prior to study and developed resistance 
to hormonal therapy. We couldn’t find other results concern-
ing relationship of BCL2 expression and molecular subtypes 
throughout progression.
Regarding the involvement of BCL2 in metastatic process 
our results are in contradiction with data of other groups, 
which reported an increase of BCL2 expression in axillary 
metastases [34, 35]. Another study reported a similar BCL2 
expression between the primary tumor and lymph node 
metastases [36]. The differences with our study are related 
to a number of cases (Mimori et al. with 6 cases, Arun et al. 
and Kristek et al. with 60 cases each), method of markers as-
sessment (cDNA microarray at Mimori et al.) and the most 
important, that all of them reported BCL2 expression from 
classical, histopathological position of breast cancer inter-
pretation (34-36). A direct and comprehensive comparison 
from molecular position of BCL2 expression between pri-
mary breast carcinomas and paired distant metastases has 
not been performed yet.
In summary, molecular subtypes and BCL2 expression 
are not stable during tumor progression and metastatic 
development. In the present study we established immuno-
histochemically that BCL2 is not influenced by subtypes’ 
transitions. BCL2 switches were encountered only in cases 
with a stable HER2, Luminal A or B phenotypes. Due to its 
dual function, promoting cell cycle arrest and preventing 
apoptosis, many things concerning BCL2 implication in 
breast cancer progression and drug resistance remain still 
unclear. Its specific localization at the crossroads of several 
complex physiological pathways, may lead to unexpected 
consequences, interesting for researches, dangerous for 
patients.
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